Exercise as a Mean to Control Low-Grade Systemic Inflammation by Mathur, Neha & Pedersen, Bente Klarlund
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2008, Article ID 109502, 6 pages
doi:10.1155/2008/109502
ReviewArticle
Exercise as a Mean to Control Low-Grade
Systemic Inﬂammation
Neha Mathur and Bente Klarlund Pedersen
The Centre of Inﬂammation and Metabolism (CIM), Department of Infectious Diseases and CMRC, Rigshospitalet,
Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
Correspondence should be addressed to Bente Klarlund Pedersen, bkp@rh.dk
Received 29 July 2008; Accepted 11 November 2008
Recommended by Eric Morand
Chronic noncommunicable diseases (CNCDs), which include cardiovascular disease, some cancers, for example, colon cancer,
breast cancer, and type 2 diabetes, are reaching epidemic proportions worldwide. It has now become clear that low-grade chronic
inﬂammation is a key player in the pathogenesis of most CNCDs. Given that regular exercise oﬀers protection against all causes
of mortality, primarily by protection against atherosclerosis and insulin resistance, we suggest that exercise may exert some of its
beneﬁcial health eﬀects by inducing anti-inﬂammatory actions. Recently, IL-6 was introduced as the ﬁrst myokine, deﬁned as a
cytokine, which is produced and released by contracting skeletal muscle ﬁbres, exerting its eﬀects in other organs of the body. We
suggest that skeletal muscle is an endocrine organ and that myokines may be involved in mediating the beneﬁcial eﬀects against
CNCDs associated with low-grade inﬂammation.
Copyright © 2008 N. Mathur and B. K. Pedersen. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Chronic noncommunicable diseases (CNCDs) which in-
clude cardiovascular conditions (mainly heart diseases and
stroke), some cancers, chronic respiratory conditions, and
type 2 diabetes, aﬀect people of all nationalities and classes
and are reaching epidemic proportions worldwide [1–4].
CNCDs cause the greatest global share of death and
disability, accounting for around 60% of all deaths world-
wide. Approximately, 80% of chronic-disease deaths occur in
low- and middle-income countries and account for 44% of
premature deaths worldwide. It is estimated that the number
of deaths from these diseases is double the number of
deaths that result from a combination of infectious diseases
(including HIV/AIDS, tuberculosis, and malaria), mater-
nal and perinatal conditions, and nutritional deﬁciencies
[1].
From a historical perspective, inﬂammation has been
consideredasthenaturalhostresponsetoanacuteinfectious
episode, whereas chronic inﬂammation has been considered
a sign of chronic infection. It has now become clear that
low-grade chronic inﬂammation is a key player in the
pathogenesis of most NCDCs. There has been an increasing
appreciation of the role of inﬂammation both in the
pathogenesis of atherosclerosis [5, 6] and as a key factor in
insulin resistance [7]. Low-grade chronic inﬂammation is
characterized by increased systemic levels of some cytokines
and C-reactive protein (CRP) and a number of studies
have conﬁrmed an association between low-grade systemic
inﬂammation on one hand and atherosclerosis and type 2
diabetes on the other [8].
Physical inactivity has been identiﬁed as a stronger
predictor of these chronic diseases than risk factors such
as hypertension, hyperlipidemia, diabetes, and obesity for
all-cause mortality [9]. Moreover, regular physical activity
appears to protect against premature death independent of
obesity [10, 11].
Regular physical activity oﬀers protection against, and
may be useful as a treatment for a wide variety of, chronic
diseases associated with low-grade inﬂammation [12]. The
protective eﬀects of regular exercise against diseases such as
cardiovascular disease, type 2 diabetes, colon cancer, and
breast cancer have been reviewed extensively [13–16].
Recent ﬁndings demonstrate that physical activity
induces an increase in the systemic levels of a number of
cytokines with anti-inﬂammatory properties [8, 17]a n d2 Mediators of Inﬂammation
skeletal muscle has recently been identiﬁed as an endocrine
organ, which produces and releases cytokines (also called
myokines) [18, 19].
The discovery of contracting muscle as a cytokine-
producing organ opens a new paradigm; skeletal muscle
is an endocrine organ that, by contraction, stimulates the
production and release of myokines, which may inﬂuence
metabolism and modify cytokine production in tissue and
organs.
2. CHRONIC LOW-GRADE SYSTEMIC INFLAMMATION
AND ITS CONSEQUENCES
In response to an acute infection or trauma, the cytokines
and cytokines inhibitors will increase [20]. The initial
cytokines as they appear in the circulation in relation to
an acute infection consist of the following: TNF-α,I L - 1 β,
IL-6, IL-1 receptor antagonist (IL-1ra), and soluble TNF-
α-receptors (sTNF-R), and IL-10. The systemic response
known as the acute-phase response includes the produc-
tion of a large number of hepatocyte-derived acute phase
proteins, such as C-reactive protein (CRP) that is known
to be a sensitive marker of systemic inﬂammation. The
response can be mimicked by the injection of the cytokines
TNF-α,I L - 1 β, and IL-6 into laboratory animals or humans
[8, 21]. Chronic low-grade systemic inﬂammation has been
characterized by a 2- to 3-fold elevation in the systemic
concentrations of proinﬂammatory and anti-inﬂammatory
cytokines, natural occurring cytokine antagonists, and the
acute phase reactant C-reactive protein (CRP) [13, 22]. In
thelattercase,thestimuliforthecytokineproductionarenot
known, but it is assumed that the origin of TNF in chronic
low-gradesystemicinﬂammationismainlytheadiposetissue
[23–26].
Type 2 diabetes, obesity, and cardiovascular disease are
related to a state of low-grade systemic inﬂammation [7,
27–29]. Despite the fact that the changes in acute-phase
reactantsaremuchsmallerthanthoseinacuteinfections,the
chronicity of low-grade inﬂammation is strongly associated
with increasing age, lifestyle factors such as smoking and
obesity,togetherwithincreasedriskofcardiovasculardisease
and type 2 diabetes [22, 25, 30]. Plasma concentrations of
IL-6 [31]a n dT N F - α have been shown to predict the risk of
myocardial infarction in several studies [32], and CRP has
emerged as a particularly stronger independent risk factor
for cardiovascular disease than the low-density lipoprotein
cholesterol level [13, 33, 34].
3. THE DIRECT METABOLIC ROLES OF TNF
Growing evidence suggests that TNF-α plays a direct role in
metabolic syndrome, via direct eﬀect of TNF-α on insulin
signaling [35, 36]. Patients with diabetes demonstrate high
expression of TNF-α in skeletal muscle and in plasma, and
it is likely that adipose tissue, which produces TNF-α, is the
main source of the circulating TNF-α [37–39].
Thus,anumberofstudiesindicatethatelevatedTNF-αis
not secondary to the pathological conditions associated with
insulin resistance, but that TNF-α plays a direct pathogenic
role in glucose metabolism [29, 40]. After adjustment
for multiple confounders, including IL-6, high plasma
TNF concentrations are associated with insulin resistance
[40].
In cultured cells, TNF-α induces insulin resistance
through increased serine phosphorylationof insulin receptor
substrate-1(IRS-1),whichsubsequentlyconvertsIRS-1toan
inhibitor of insulin receptor tyrosinekinase activity [41].
TNF-α has been shown to have a direct (insulin-
independent) eﬀecton S6K and ERK-1/2 in cultured cells
[42, 43].
In addition, evidence for a direct role of TNF-α in insulin
resistance in humans in vivo has been obtained [44]. When
TNF-αwasinfusedintohealthyhumans,wefoundthatTNF-
α induces insulin resistance in skeletal muscle, without an
eﬀect on endogenous glucose production. TNF-α directly
impaired glucose uptake and metabolism by altering insulin
signal transduction. TNF-alpha infusion increased phos-
phorylation of p70 S6 kinase, extracellular signal-regulated
kinase-1/2, and c-Jun NH(2)-terminal kinase, concomitant
with increased serine and reduced tyrosine phosphorylation
of insulin receptor substrate-1. These signalling eﬀects were
associated with impaired phosphorylation of Akt substrate
160, the most proximal step identiﬁed in the canonical
insulin signalling cascade regulating GLUT4 translocation
and glucose uptake. Thus, excessive concentrations of TNF-
alpha negatively regulate insulin signalling and whole-body
g l u c o s eu p t a k ei nh u m a n s .
Moreover, it was recently demonstrated that TNF-alpha
infusion increases whole-body lipolysis by 40% with a
concomitant increase in FFA clearance, but with no changes
in skeletal muscle FFA uptake, release, or oxidation [45].
The ﬁndings with regard to an eﬀect of TNF on both
glucose and fat metabolism provide a direct molecular link
betweenlow-gradesystemicinﬂammationandthemetabolic
syndrome [44, 45].
4. THE DIRECT METABOLIC ROLES OF IL-6
With regard to IL-6, its role in insulin resistance is highly
controversial. In humans, circulating IL-6 levels may [46]o r
may not [47] be associated with insulin resistance.
Infusion of recombinant human (rh) IL-6 into resting
healthy humans does not impair whole body, lower limb, or
subcutaneous adipose tissue glucose uptake or endogenous
glucose production [48, 49]. When diabetes patients were
given an rhIL-6 infusion, plasma concentrations of insulin
decreased to levels comparable with that in age and BMI
(body mass index)-matched healthy controls, indicating that
the IL-6 enhanced insulin sensitivity [50].
In vitro studies demonstrate that IL-6 can induce insulin
resistance in isolated 3T3-L1 adipocytes [51, 52] and in
mice [53]. However, the IL-6 dose applied in the latter
studies was supraphysiological, and is therefore probably not
relevant to human physiology. Interestingly, IL-6 knockout
mice develop impaired glucose tolerance that is reverted by
IL-6. Thus, accumulating data suggest that IL-6 enhances
g l u c o s eu p t a k ei nm y o c y t e s[ 54–57].N. Mathur and B. K. Pedersen 3
AnumberofstudiesindicatethatIL-6enhanceslipolysis,
as well as fat oxidation [50, 58]. Consistent with this idea,
Wallenius et al. 2002 demonstrated that IL-6 deﬁcient mice
developed mature-onset obesity and insulin resistance. In
addition, when the mice were treated with IL-6, there was a
signiﬁcant decrease in body fat mass in the IL-6 knockout
but not in the wild-type mice. Recently, we demonstrated
that IL-6 increased the glucose infusion rate [56]a n dgl u c o s e
oxidation without aﬀecting the suppression of endogenous
glucose production during a hyperinsulinemic euglycemic
clamp in healthy humans. Infusion of rhIL-6 into healthy
humans to obtain physiological concentrations of IL-6
increased lipolysis in the absence of hypertriacylglyceridemia
or changes in catecholamines, glucagon, insulin, or any
adverse eﬀects in healthy individuals as well as patients with
type2 diabetes [49, 50, 58].These ﬁndings, together with cell
culture experiments demonstrating that IL-6 alone markedly
increases both lipolysis and fat oxidation, identify IL-6 as a
novel lipolytic factor.
Taken together, it is apparent that in vivo studies in
humans provide little or no evidence that IL-6 is a direct
player in the metabolic syndrome.
5. TNF/IL-6-INTERACTION
Of note, whereas it is known that both TNF-α and IL-6
induce lipolysis [40, 49], only IL-6 appears to induce fat
oxidation [19, 59]. Given the diﬀerent biological proﬁles
of TNF-α and IL-6, and given that TNF-α can trigger IL-6
release, one theory holds that it is the adipose tissue-derived
TNF-α that actually is the “driver” behind the metabolic
syndrome [36] and that locally produced TNF-α causes
increased systemic levels of IL-6.
6. CYTOKINE RESPONSES TO EXERCISE
Though an acute bout of physical activity is accompanied by
responses that in many respects are similar to those induced
by infection and sepsis, there are some important diﬀerences
in the cytokine response to exercise from that elicited by
severe infection [27, 60, 61]. The striking diﬀerence between
exercise and sepsis with regard to cytokine responses is that
the classical proinﬂammatory cytokines, TNF-α and IL-1β,
in general do not increase with exercise.
Typically, IL-6 is the ﬁrst cytokine present in the
circulation during exercise, and the appearance of IL-6 in
the circulation is by far the most marked and its appearance
precedes that of the other cytokines. The level of circulating
IL-6 increases in an exponential fashion (up to 100 fold) in
response to exercise, and declines in the postexercise period
[60–62].
Taken together, exercise provokes an increase primarily
in IL-6, followed by an increase in IL-1ra and IL-10. The
IL-6 response to exercise has recently been reviewed [13,
18, 60, 63]. A marked increase in circulating levels of IL-6
after exercise without muscle damage has been a remarkably
consistent ﬁnding. The magnitude by which plasma IL-6
increasesisrelatedtoexerciseduration, intensity, andmuscle
mass involved in the mechanical work [13, 18, 60, 62].
7. ANTI-INFLAMMATORY EFFECTS OF IL-6
Interleukin-6 is most often classiﬁed as a proinﬂammatory
cytokine, although data also suggest that IL-6 and IL-6-
regulated acute phase proteins are anti-inﬂammatory and
immunosuppressive, and may negatively regulate the acute-
p h a s er e s p o n s e[ 20].
A number of studies have demonstrated that working
muscle produces IL-6. Thus muscle biopsies obtained before
and after exercise in humans and rats demonstrate very
little IL-6 mRNA in resting muscle, but up to a 100-
fold increase in exercising skeletal muscle [18, 64, 65]. In
addition, it has been demonstrated that the IL-6 protein
is expressed in contracting muscle ﬁbres and that IL-6 is
released from skeletal muscle during exercise [28]. Data
suggest that IL-6 exerts inhibitory eﬀects on TNF-α and IL-1
production. IL-6 inhibits lipopolysaccharide (LPS)-induced
TNF-α production both in cultured human monocytes and
in the human monocytic line U937 [66], and levels of
TNF-α are markedly elevated in anti-IL-6-treated mice and
in IL-6-deﬁcient knockout mice [67, 68], indicating that
circulating IL-6 is involved in the regulation of TNF-α
levels. In addition, rhIL-6 infusion inhibits the endotoxin-
induced increase in circulating levels of TNF-α in healthy
humans [69]. Furthermore, IL-6 stimulates the release of
soluble TNF-α receptors, but not IL-1β and TNF-α,a n d
appears to be the primary inducer of the hepatocyte-derived
acute-phaseproteins,manyofwhichhaveanti-inﬂammatory
properties.
The exercise-induced increase in plasma IL-6 levels is
followed by increased circulating levels of well-known anti-
inﬂammatory cytokines such as IL-1ra and IL-10 [28, 48].
It has been suggested that IL-6 promotes insulin resis-
tance due to the observation that plasma IL-6 is often
elevated in patients with metabolic disease [70].
From a simplistic physiological point of view, it seems
paradoxical that working muscle would release a factor
that inhibits insulin signalling when insulin sensitivity is
enhanced in the immediate postexercise period [28].
8. ANTI-INFLAMMATORY EFFECTS OF EXERCISE
A number of studies suggest that regular exercise has anti-
inﬂammatory eﬀects. Cross-sectional studies demonstrate
an association between physical inactivity and low-grade
systemic inﬂammation in healthy subjects [71–75], in elderly
people [76, 77], and in patients with intermittent claudica-
tion [78]. Moreover, the ﬁnding in longitudinal studies that
regular training induces a reduction in CRP level suggests
that the physical activity as such may suppress systemic low-
grade inﬂammation [74, 75, 79, 80].
To study whether acute exercise induces a true anti-
inﬂammatory response, a model of “low-grade inﬂamma-
tion” was established in which we injected a low dose of
Escherichia coli endotoxin to healthy volunteers, who had
been randomized to either rest or exercise prior to endotoxin
administration. In resting subjects, endotoxin induced a 2-
to 3-fold increase in circulating levels of TNF-α. In contrast,
when the subjects performed 3 hours of ergometer cycling4 Mediators of Inﬂammation
and received the endotoxin bolus at 2.5 hours , the TNF-α
response was totally blunted. Moreover, the eﬀect of exercise
could be mimicked by infusion of IL-6, suggesting that IL-6
may be involved in mediating the anti-inﬂammatory eﬀects
of exercise [69].
9. CONCLUSION
Regular exercise protects against diseases associated with
chronic low-grade systemic inﬂammation. Muscle con-
traction-induced factors, so-called myokines, may be in-
volved in mediating the health beneﬁcial eﬀects of exercise
and play important roles in the protection against CNCDs,
which include cardiovascular conditions, some cancers, and
type 2 diabetes. In particular, the long-term eﬀect of exercise
may to some extent be ascribed to the anti-inﬂammatory
response elicited by an acute bout of exercise, which is partly
m e d i a t e db ym u s c l e - d e r i v e dI L - 6[ 8, 20, 81]. The possibility
exists that, with regular exercise, the anti-inﬂammatory
eﬀects of an acute bout of exercise will protect against
chronicsystemic low-grade inﬂammation and thereby oﬀer
protection against insulin resistance and the development of
atherosclerosis, but such a link between the acute eﬀects of
exercise and the long-term beneﬁts has not yet been proven.
Given that the atherosclerotic process is characterized by
inﬂammation,onealternativeexplanationwouldbethatreg-
ular exercise, which oﬀers protection against atherosclerosis,
indirectly oﬀers protection against vascular inﬂammation
and hence systemic low-grade inﬂammation.
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